CIK 0001817713
- Large accelerated filer
Janux Therapeutics, Inc.
Sign in to watch- Ticker
- JANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822289112
- Phone
- +1 858-751-4493
- Business address
- 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +304,287 | $30.56 | $9.3M | 9,621,533 |
| 2025-03-05 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +37,455 | $31.30 | $1.2M | 9,658,988 |
| 2025-03-03 | Meyer Andrew Hollman Chief Business Officer | Option exercise 10b5-1 | +3,334 | $4.21 | $14K | 85,473 |
| 2025-03-03 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −2,433 | $31.88 | $78K | 83,040 |
| 2025-03-03 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −901 | $32.85 | $30K | 82,139 |
| 2025-03-03 | Meyer Andrew Hollman Chief Business Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,334 | 93,999 | ||
| 2025-02-03 | Meyer Andrew Hollman Chief Business Officer | Option exercise 10b5-1 | +3,334 | $4.21 | $14K | 85,473 |
| 2025-02-03 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −2,418 | $42.08 | $102K | 83,055 |
| 2025-02-03 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −816 | $42.77 | $35K | 82,239 |
| 2025-02-03 | Meyer Andrew Hollman Chief Business Officer | Sale 10b5-1 | −100 | $43.60 | $4K | 82,139 |
| 2025-02-03 | Meyer Andrew Hollman Chief Business Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,334 | 97,333 | ||
| 2025-01-07 | Campbell David Alan President and CEO | Sale 10b5-1 | −5,000 | $60.00 | $300K | 293,054 |
| 2025-01-02 | McIver Zachariah Chief Medical Officer | Grant or award | +26,000 | 26,000 | ||
| 2025-01-02 | McIver Zachariah Chief Medical Officer | Grant or award · Stock option (right to buy) | +91,000 | 91,000 | ||
| 2025-01-02 | Winter Charles M. Chief Technical Officer | Grant or award | +23,000 | 77,288 | ||
| 2025-01-02 | Winter Charles M. Chief Technical Officer | Grant or award · Stock option (right to buy) | +80,500 | 80,500 | ||
| 2025-01-02 | Campbell David Alan President and CEO | Grant or award | +81,000 | 298,054 | ||
| 2025-01-02 | Campbell David Alan President and CEO | Grant or award · Stock option (right to buy) | +283,500 | 283,500 | ||
| 2025-01-02 | Robinson Byron Chief Strategy Officer | Grant or award | +28,000 | 28,000 | ||
| 2025-01-02 | Robinson Byron Chief Strategy Officer | Grant or award · Stock option (right to buy) | +98,000 | 98,000 |
Page 5 of 15 · 294 trades